PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32245294-2	2019	Our previous work indicated that idarubicin-ZHER2 affibody conjugate has a great potential for the treatment of HER2-overexpressing malignant cell lines but possible induced immune response against constructed conjugate was not addressed.	Idarubicin	33-43	erb-b2 receptor tyrosine kinase 2	Homo sapiens	45-49	
28460618-0	2019	Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate.	Idarubicin	86-96	erb-b2 receptor tyrosine kinase 2	Homo sapiens	22-26	
28460618-2	2019	OBJECTIVE: In the current study, HER2-specific affibody molecule, ZHER2:342 (an engineered protein with great affinity for HER2 receptors) was selected for conjugation to idarubicin (an anti-neoplastic antibiotic).	Idarubicin	171-181	erb-b2 receptor tyrosine kinase 2	Homo sapiens	33-37	
28460618-2	2019	OBJECTIVE: In the current study, HER2-specific affibody molecule, ZHER2:342 (an engineered protein with great affinity for HER2 receptors) was selected for conjugation to idarubicin (an anti-neoplastic antibiotic).	Idarubicin	171-181	erb-b2 receptor tyrosine kinase 2	Homo sapiens	67-71	
33936221-5	2021	In the current study, we assessed the cytotoxic effects of idarubicin-ZHER2 affibody conjugate on the positive-HER2 cancer cell lines.	Idarubicin	59-69	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-75	
33936221-10	2021	Conclusion: The ZHER2-affibody conjugate of idarubicin has a more specific cytotoxic effect compared with idarubicin alone against HER2-overexpressing ovarian cancerous cells.	Idarubicin	44-54	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21	
33936221-10	2021	Conclusion: The ZHER2-affibody conjugate of idarubicin has a more specific cytotoxic effect compared with idarubicin alone against HER2-overexpressing ovarian cancerous cells.	Idarubicin	106-116	erb-b2 receptor tyrosine kinase 2	Homo sapiens	17-21	
33936221-11	2021	It appears the ZHER2-affibody conjugate of idarubicin has great potential to be implicated as an innovative anti-cancer agent in future clinical trials in patients with HER2-overexpressing ovarian cancer.	Idarubicin	43-53	erb-b2 receptor tyrosine kinase 2	Homo sapiens	16-20